Amneal Pharmaceuticals (AMRX) reported Q4 adjusted earnings Friday of $0.12 per diluted share, down from $0.14 a year earlier.
Four analysts polled by FactSet expected $0.15.
Revenue for the quarter ended Dec. 31 was $730.5 million compared with $617 million a year earlier.
Three analysts surveyed by FactSet expected $708.1 million.
The company said it expects 2025 adjusted EPS of $0.65 to $0.70 on revenue of $3 billion to $3.1 billion. Analysts surveyed by FactSet expect $0.71 and $2.92 billion, respectively.
Amneal shares were up 2.6% in recent premarket activity.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。